Pharmacological models in healthy volunteers: Their use in the clinical development of psychotropic drugs

Journal of Psychopharmacology

Volumn 21, Issue 3, 2007, Pages 272-282

  Gilles, Christian ^a   Luthringer, Remy ^b,c  

^a Centre Hospitalier de l'Ardenne   (Belgium)

^b FORENAP   (France)

^c Forenap Pharma   (France)

Author keywords

Apomorphine; CCK 4; Drug development; Healthy volunteers; Ketamine; Lorazepam; Models; Panic; Scopolamine; Tryptophan depletion test

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ALPRAZOLAM; APOMORPHINE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CLONIDINE; CLOZAPINE; DIAZEPAM; FLUVOXAMINE; HALOPERIDOL; KETAMINE; LORAZEPAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLANZAPINE; ONDANSETRON; PHENCYCLIDINE; PROPRANOLOL DERIVATIVE; PSYCHOTROPIC AGENT; SCOPOLAMINE; TETRAGASTRIN DERIVATIVE; TIAGABINE; TRYPTOPHAN; VIGABATRIN; YOHIMBINE;

ANXIETY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FACE VALIDITY; HUMAN; NONHUMAN; PANIC; PATHOPHYSIOLOGY; POPULATION MODEL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TEST RETEST RELIABILITY; TREATMENT RESPONSE; VOLUNTEER;

APOMORPHINE; COGNITION DISORDERS; DOPAMINE AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GABA MODULATORS; HUMANS; KETAMINE; LORAZEPAM; MEMORY DISORDERS; MODELS, PSYCHOLOGICAL; MUSCARINIC ANTAGONISTS; PANIC DISORDER; PSYCHOTROPIC DRUGS; SCOPOLAMINE; TRYPTOPHAN;

EID: 34250618703     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107077733     Document Type: Review

References (104)

1. Barker A., Jones R., Prior J., Wesnes K. (1998) Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up. Int J Geriat Psychiatry 13: 244 - 247
2. Benjamin J., Greenberg B.D., Murphy D.L. (1996) Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology 127: 140 - 149
3. Benjamin J., Geraci M., McCann U., Greenberg B.D., Murphy D.L. (1999) Attenuated response to m-CPP and to pentagastrin after repeated m-CPP in panic disorder. Psychopharmacology 143: 215 - 216
4. Benkelfat C., Bradwejn J., Meyer E., Ellenbogen M., Milot S., Gjedde A., Evans A. (1995) Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152: 1180 - 1184
5. Bhatti T., Gillin J.C., Seifritz E., Moore P., Clark C., Golshan S., Stahl S., Rapaport M., Kelsoe J. (1998) Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and sleep. Biol Psychiatry 43: 52 - 59
6. Booij L., Van der Does A J W, Riedel W J. (2003) Monoamine depletion in psychiatric and healthy populations: review. Mol Psychiatry 8: 951 - 973
7. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes (1991) Acta Neuropathol 82: 239 - 259
8. Bradwejn J., Koszycki D., Shriqui C. (1991 a) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Am J Psychiatry 151: 603 - 610
9. Bradwejn J., Koszycki D., Bourin M. (1991 b) Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatr Neurosci 16: 91 - 95
10. Bradwejn J., Koszycki D., Payeur R., Bourin M., Borthwick H. (1992) Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am J Psychiatry 149: 962 - 964
11. Bradwejn J., Koszycki D., Couëtoux du Tertre A., paradis M., Bourin M. (1994) Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Psychopharmacology 114: 257 - 261
12. Bradwejn J., Koszycki D., Paradis M., Reece P., Hinton J., Sedman A. (1995) Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38: 742 - 746
13. Bradwejn J., LeGrand J.M., Koszycki D., Bates J H T, Bourin M. (1998) Effects of cholecystokinin tetrapeptide on respiratory functions in healthy volunteers. Am J Psychiatry 155: 280 - 282
14. Cameron O.G., Modell J.G., Hariharan M. (1990) Caffeine in human cerebral blood flow: a positron emission tomography study. Life Sci 47: 1141 - 1146
15. Cameron O.G., Zubieta J.K., Grunhaus L., Minoshima S. (2000) Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom Med 62: 549 - 559
16. Carpenter L.L., Anderson G.M., Pelton G.H., Gudin J.A., Kirwin P D S, Price L.H., Heninger G.R., McDougle C.J. (1998) Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 19: 26 - 35
17. Charney D.S., Heninger G.R., Redmond D Jr (1983) Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci 33: 19 - 29
18. Charney D.S., Woods S.W., Goodman W.K., Heninger G.R. Serotonin function in anxiety (1987) II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92: 14 - 24
19. Charney D.S., Woods S.W., Krystal J.H., Nagy L.M., Heninger G.R. (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86: 273 - 282
20. Cowley D.S., Arana G.W. (1990) The diagnostic utility of lactate sensitivity in panic disorder. Arch Gen Psychiatry 47: 277 - 284
21. Curran H.V., Schiwy W., Lader M. (1987) Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacology 92: 358 - 364
22. Curran H.V. (1991) Benzodiazepines, memory and mood: a review. Psychopharmacology 105: 1 - 8
23. Curran H.V., Schifano F., Lader M. (1991) Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 103: 83 - 90
24. de Montigny C. (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry 46: 511 - 517
25. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Henninger G.R. (1990) Serotonin function and the mechanism of antidepressant action. Arch Gen Psychiatry 47: 411 - 418
26. Depôt D., Caillé G., Mukherjee J., Katzman M.A., Cadieux A., Bradwejn J. (1999) Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology 20: 177 - 187
27. Drachman D.A., Leavitt J. (1974) Human memory and the cholinergic system: a relationship to aging? Arch Neurol 30: 113 - 121
28. Duka T., Redeman B., Voet B. (1995) Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing. Psychopharmacology 119: 315 - 324
29. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. (1998) Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65 - 75
30. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. (2000) Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293: 8 - 14
31. Duncan G.E., Miyamoto S., Lieberman J.A. (2003) Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 305: 999 - 1005
32. Ebert U., Kirch W. (1998) Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 28: 944 - 949
33. Ebert U., Oertel R., Wesnes K., Kirch W. (1998) Effect of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance. Hum Psychopharmacol Clin Exp 13: 199 - 210
34. Flicker C., Ferris S.H., Serby M. (1992) Hypersensitivity to scopolamine in the elderly. Psychopharmacology 107: 437 - 441
35. Flint A.J., Koszycki D., Vaccarino F.J., Cadieux A., Boulenger J.P., Bradwejn J. (1998) Effect of aging on cholecystokinin-induced panic. Am J Psychiatry 155: 283 - 285
36. Food and Drug Administration: www.fda.gov/cder/handbook/phase1.htm. FDA: Rockville, MD. Accessed on 05.06.2005
37. Galderisi S., Mucci A., Bucci P., Mignone M.L., Maj, M. (1996) Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Res 67: 113 - 122
38. Germine M., Goddard A.W., Sholomskas D.E., Woods S.W., Charney D.S., Heninger G.R. (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54: 115 - 133
39. Gorman J.M., Fyer M.R., Liebowutz M.R., Klein D.F. (1987) Pharmacologic provocation of panic attacks. In Meltzer H Y (ed.). Psychopharmacology: The third generation of progress. Raven Press, New York
40. Graeff F.G., Parente A., Del-Ben C.M., Guimaraes F.S. (2003) Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421 - 432
41. Guttmacher L.B., Murphy D.L., Insel T.R. (1983) Pharmacologic models of anxiety. Compr Psychiatry 24: 312 - 326
42. Hughes A.M., Lynch P., Rhodes J., Ervine C.M., Yates R.A. (1999) Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Br J Clin Pharmacol 48: 323 - 330
43. Javanmard M., Shlik J., Kennedy S.H., Vaccarino F.J., Houle S., Bradwejn J. (1999) Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry 45: 872 - 882
44. Jones R.W., Wesnes K.A., Kirby J. (1991) Effects of NMDA modulation in scopolamine dementia. Ann NY Acad Sci 640: 241 - 244
45. Kahn R.S., Wetzler S., Asnis G.M., Kling M.A., Suckow R.F., van Praag H.M. (1990) Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 100: 339 - 344
46. Ketter T.A., Andreason P.J., George M.S., Lee C., Gill D.S., Parekh P.I. (1996) Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Arch Gen Psychiatry 53: 59 - 69
47. Koszycki D., Cox B.J., Bradwejn J. (1993). Anxiety sensitivity and response to cholecystokinin tertrapeptide in healthy volunteers. Am J Psychiatry 150: 1881 - 1883
48. Koszycki D., Zacharko R.M., Le Medello J.M., Bradwejn J. (1998) Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety 8: 1 - 7
49. Krystal J.H., D'Souza D.C., Karper L.P., Bennet A., Abi-Dargham A., Abi-Saab D., Bowers M.B. Jr, Jatlow P., Heininger G.R., Charney D.S. (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145: 193 - 204
50. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 169: 215 - 233
51. Lahti A.C., Holcomb H.H. (2003) Schizophrenia, VIII. Pharmacologic models. Am J Psychiatry 160: 2091
52. Le Mellédo J.M., Bradwejn J., Koszycki D., Bichet D.G., Bellavance F. (1998) The role of the beta-noradrenergic system in chlolecystokinintetrapeptide-induced panic symptoms. Biol Psychiatry 44: 364 - 366
53. Leyton M., Young S.N., Pihl R.O., Etezadi S., Lauze C., Blier P., Baker G.B., Benkelfat C. (2000) Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology 22: 52 - 63
54. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81: 363 - 369
55. Luthringer R. (1998) Evaluation de la sphère dopaminergique cérébrale chez l'homme. Mise au point, validation, caractérisation et intérêt du test à l'apomorphine sous surveillance électroencéphalographique. Thesis, Louis Pasteur University, Strasbourg
56. Luthringer R., Rinaudo G., Toussaint M., Bailey P., Muller G., Muzet A., Macher J.P. (1999) Electroencephaphic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. Neuropsychobiology 39: 49 - 56
57. Mandema J.W., Danhof M. (1992) Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally active drugs. Clin Pharmacokinet 23: 191 - 215
58. Mathew R.J., Wilson W.H. (1985) Caffeine induced changes in cerebral circulation. Stroke 16: 814 - 817
59. Mathew R.J., Wilson W.H. (1990) Behavioral and cerebrovsacular effects of caffeine in patients with anxiety disorders. Acta Psychiatr Scand 82: 17 - 22
60. McClelland G.R., Cooper S.M., Pilgrim A.J. (1990) A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 30: 795 - 803
61. Meyer J.H., Kapur S., Wilson A.A., DaSilva J.N., Houle S., Brown G.M. (1996) Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: an [15O]H2O PET study in humans. Neurosci Lett 207: 25 - 28
62. Meyer J.H., Swinson R., Kennedy S.H., Houle S., Brown G.M. (2000) Increased left posterior parietal-temporal cortex activation after d-fenfluramine in women with panic disorder. Psychiatry Res 98: 133 - 143
63. Molchan S.E., Mellow A.M., Lawlor B.A., Weingartner H.J., Cohen R.M., Cohen M.R., Sunderland T. (1990) TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology 100: 84 - 89
64. Moore P., Gillin J.C., Bhatti T., Demodena A., Seifritz E., Clark C., Stahl S., Rapaport M., Kelsoe J. (1998) Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 55: 534 - 539
65. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., Kelsoe J., Rapaport M., Gillin C. (2000) Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology 23: 601 - 622
66. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., Blier P., Diksic M. (1997) Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci 94: 4823 - 4824
67. Northoff G., Richter A., Bermpohl F., Grimm S., Martin E., Marcar V.L., Wahl C., Hell D., Boeker H. (2005) NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 72: 235 - 248
68. Pandit U.A., Kothary S.P., Samra S.K., Domino E.F., Pandit S.K. (1983) Physostigmine fails to reverse clinical, psychomotor, or EEG effects of lorazepam. Anesth Analg 62: 679 - 685
69. Preston G.C., Broks P., Traub M., Ward C., Poppleton P., Stahl S.M. (1988) Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology 95: 208 - 215
70. Preston G.C., Ward C., Lines C.R., Poppteton P., Haigh J.R., Traub M. (1989) Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. Psychopharmacology (Berl) 98: 487 - 494
71. Przedborski S., Levivier M., Raftopoulos C., Naini A.B., Hildebrand J. (1995) Peripheral and central pharmacokinetics of apomorphine and its effects on dopamine metabolism in humans. Mov Disord 10: 28 - 36
72. Rainey J.M., Pohl R.B., Williams M., Knitter E., Freedman R.R., Ettedgui E. (1984) A comparison of lactate and isoproterenol anxiety states. Psychopathology Suppl 1: 74 - 82
73. Reuter-Lorenz P.A., Lustig C. (2005) Brain aging: reorganizing discoveries about the aging mind. Curr Opin Neurobiol 15: 245 - 251
74. Rijnbeek B., de Visser S.J., Franson K.L., Cohen A.F., van Gerven J.M. (2003) REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 17: 196 - 203
75. Robinson D.S., Rickels K. (2000) Concerns about clinical drug trials. J Clin Psychopharmacol 20: 593 - 596
76. Sanderson W.C., Wetzler S. (1990) Five percent carbon dioxide challenge: valid analogue and marker of panic disorder? Biol Psychiatry 27: 689 - 701
77. Sandford J.J., Argyropoulos S.V., Nutt D.J. (2000) The psychobiology of anxiolytic drugs. Part 1: basic neurobiology. Pharmacol Ther 88: 197 - 212
78. Schon K., Atri A., Hasselmo M.E., Tricarico M.D., LoPresti M.L., Stern C.E. (2005) Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans. J Neurosci 25: 9112 - 9123
79. Schunck T., Erb G., Mathis A., Gilles C., Namer I.J., Hode Y., Demaziere A., Luthringer R., Macher J.P. (2006) Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31: 1197 - 1208
80. Servan-Schreiber D., Perlstein W.M., Cohen J.D., Mintun M. (1998) Selective pharmacological activation of limbic structures in human volunteers. A positron emission tomography study. J Neuropsychiatry Clin Neurosci 10: 148 - 159
81. Sevy S., Brown S.L., Wetzler S., Kotler M., Molcho A., Plutchik R., van Praag H.M. (1994) Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res 53: 219 - 229
82. Shillinford C.A., Vose C.W. (2001) Effective decision-making: progressing compounds through clinical development. Drug Discov Today 6: 941 - 946
83. Shlik J., Vasar V., Aluoja A., Kingisepp P.H., Jagomagi K., Vasar E., Rago L., Bradwejn J. (1997) The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry 42: 206 - 212
84. Siegfrid K.R. (1993) Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 149: 26 - 28
85. Sperling R., Greve D., Dale A., Killiany R., Holmes J., Rosas H.D., Cocchiarella A., Firth P., Rosen B., Lake S., Lange N., Routledge C., Albert M. (2002) Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci USA 99: 455 - 460
86. Stancampiano R., Melis F., Sarais L., Cocco S., Cugusi C., Fadda F. (1997) Acute administration of a tryptophan-free amino acid mixture decreases 5-HT release in rat hippocampus in vivo. Am J Physiol 272: R991 - R994
87. Staner L., Luthringer R., Macher J.P. (1999) The effects of antidepressant drugs on sleep EEG in major depression: mechanisms and therapeutic implications CNS Drugs 11: 49 - 60
88. Staner L., Luthringer R., Le Bon O. (2006) Sleep disturbances in affective disorders. In Pandi-Perumal S R, Monti J M (eds) Clinical Pharmacology of Sleep. Springer, Berlin
89. Sunderland T., Tariot P., Murphy D.L., Weingartner H., Mueller E.A., Cohen R.M. (1985) Scopolamine challenges in Alzheimer's disease. Psychopharmacology 87: 247 - 249
90. Targum S.D. (1991) Panic attack frequency and vulnerability to anxiogenic challenge studies. Psychiatry Res 36: 75 - 83
91. Thiel C.M., Henson R.N., Dolan R.J. (2002) Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study. Neuropsychopharmacology 27: 282 - 292
92. Uhde T.W., Boulenger J.P., Jimerson D.C., Post R.M. (1984) Caffeine: relationship to human anxiety, plasma MHPG and cortisol. Psychopharmacol Bull 20: 426 - 430
93. Van der Does A J W (2001) The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord 64: 107 - 119
94. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S). and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25 - 38
95. Vordeholzer U., Hornyak M., Thiel B., Huwig-Poppe C., Kiemen A., König A., Backhaus J., Riemann D., Berger M., Hohagen F. (1998) Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology 18: 112 - 124
96. Wesnes K.A., Simpson P.M., Christmas L., Anand R., McClelland G.R. (1989) The effects of moclobemide on cognition. J Neural Transm Suppl 28: 91 - 102
97. Wesnes K., Anand R., Lorscheid T. (1990) Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiatr Scand Suppl 360: 71 - 72
98. White P.F., Schüttler J., Schafer A., Stanski D.R., Horai Y., Trevor A.J. (1985) Comparative pharmacology of the ketamine isomers. Br J Anaesth 57: 197 - 203
99. Wiedemann K., Jahn H., Yassouridis A., Kellner M. (2001) Anxiolytic like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks. Preliminary findings. Arch Gen Psychiatry 58: 371 - 377
100. Young S.N., Smith S.E., Pihl R.O., Ervin F.R. (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87: 173 - 177
101. Zangara A., Edgar C., Wesnes K., Scalafaro P., Porchet H.C. (2004) The effectiveness of ZT-1 and donepezil in reversing scopolamine-induced cognitive impairment in elderly volunteers. Int J Neuropsychopharmacol 7 (Suppl). 377
102. Zwanzger P., Baghai T.C., Schuele C., Ströhle A., Padberg F., Kathmann N. (2001) Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25: 699 - 703
103. Zwanzger P., Eser D., Aicher S., Schule C., Baghai T.C., Padberg F., Ella R., Moller H.J., Rupprecht R. (2003 a) Effect of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal- axis activity: a placebo-controlled study. Neuropsychopharmacology 28: 979 - 984
104. Zwanzger P., Eser D., Padberg F., Baghai T.C., Schule C., Rotzer F., Ella R., Moller H.J., Rupprecht R. (2003 b) Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety 18: 140 - 143K